More on reports of esophageal cancer with oral bisphosphonate use.
Solomon
Daniel H
DH
Patrick
Amanda
A
Brookhart
M Alan
MA
D000284:Administration, Oral; D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002116:Calcitonin / Q000627:therapeutic use; D004164:Diphosphonates / Q000009:adverse effects*; D004938:Esophageal Neoplasms / Q000139:chemically induced / Q000453:epidemiology*; D006801:Humans; D015994:Incidence; D010024:Osteoporosis / Q000188:drug therapy; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D018426:SEER Program; D014481:United States / Q000453:epidemiology
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D020849:Raloxifene Hydrochloride; D002116:Calcitonin